We read with great interest the Correspondence from Bhoori and colleagues[@bib1] describing the effect of coronavirus disease 2019 (COVID-19) on their centre\'s adult liver transplant population.[@bib1] Within their cohort of over 150 transplant recipients, the authors identified six patients with COVID-19, including three resulting deaths. Each of those who died was transplanted over 10 years previously and were older than 65 years, male, overweight, and had hypertension and diabetes. The authors speculated as to whether these characteristics might be major risk factors for mortality.

We operate two collaborating international registries ([SECURE Cirrhosis](https://covidcirrhosis.web.unc.edu){#interrefs10} covering the Americas, China, Japan, and South Korea; and [COVID-Hep](http://www.COVID-Hep.net){#interrefs20} covering the rest of the world) working to collate details of patients with chronic liver disease and post-liver transplantation who develop COVID-19. As of April 22, 2020, we have received submissions from 21 countries. Here, we summarise details of the 39 liver transplant recipients who developed COVID-19, including nine (23%) who died from respiratory failure ([table](#tbl1){ref-type="table"} ).TableBaseline characteristics of 39 patients with previous liver transplant and laboratory-confirmed COVID-19 submitted to the COVID-Hep and SECURE Cirrhosis registries**Survived (n=30)Died (n=9)p value**Age (years)58 (50--64)63 (61--67)0·102Sex\....0·696Male20 (67%)5 (56%)..Female10 (33%)4 (44%)..Overweight (BMI \>25 kg/m^2^)19 (63%)7 (78%)0·695Obese (BMI \>30 kg/m^2^)7 (23%)3 (33%)0·679Heart disease4 (13%)2 (22%)0·607Diabetes11 (37%)4 (44%)0·711Arterial hypertension14 (47%)4 (44%)1·000Time from transplant (years)5 (2--11)6 (1--8)0·580Baseline laboratory characteristicsSerum sodium (mmol/L)138 (137--141)138 (136--139)0·266Serum total bilirubin (μmol/L)10 (7--13)10 (8--15)0·570Serum albumin (g/L)40 (37--42)37 (33--38)0·025Serum creatinine (μmol/L)109 (80--133)141 (111--186)1·000Prothrombin time (s)12 (11--14)12 (11--15)0·930Immunosuppressive drugsPrednisone or prednisolone10 (33%)6 (67%)0·123Tacrolimus27 (90%)8 (89%)1·000Sirolimus2 (7%)0 (0%)1·000Mycophenolate mofetil16 (53%)4 (44%)0·716[^1]

By contrast with the experience of Bhoori and colleagues, the deaths in our cohort included four patients transplanted within the past 2 years, with a median age younger than 65 years, and 44% women. Among the patients who died, four (44%) had diabetes, four (44%) had hypertension, and three (33%) were obese. Although our numbers were small, the frequencies of these comorbidities were not significantly different between those of fatal and non-fatal cases of COVID-19 ([table](#tbl1){ref-type="table"}). These conflicting findings are further reinforcement that greater case numbers are urgently required to accurately inform our understanding of individual risk.

Collating and analysing rapidly emerging data will be vital for identifying modifiable risk factors for severe COVID-19 among liver transplant recipients. For example, different immunosuppression regimens might confer differential risk and changes to these medications might mitigate the risk of COVID-19 complications.

Although early data suggest that the effects of COVID-19 on the liver might be modest and reflect infection severity among patients without pre-existing liver disease, the effects of COVID-19 on those with liver transplants or established liver disease remain unclear.[@bib2] We call on all those caring for patients with previous liver transplantation and other forms of chronic liver disease to use registries to pool details of COVID-19 cases and so permit the rapid large-scale collaborative analyses that are required to inform clinical care.
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[^1]: Data are n (%) or median (IQR). BMI=body-mass index. p values were calculated using Wilcoxon rank-sum or Fisher\'s exact tests as appropriate.
